- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Medical devices called transcatheter valve-repair (TVR) devices are used to treat disorders of the heart valves without the need for open heart surgery.
These devices use catheters or other minimally invasive techniques to gain access to faulty heart valves and repair or replace them as needed.
Surgery is a common component of traditional treatment for heart valve problems, but it carries a number of dangers and can take a long time to recover from.
For individuals who are deemed high-risk or ineligible for open cardiac surgery, transcatheter valve-repair devices provide an alternate option that is less invasive.
Aortic valve regurgitation (leaking) and mitral valve regurgitation are the two valve conditions that are treated the most frequently with transcatheter valve-repair devices.
These conditions happen when the heart valves don't close properly, which lets blood flow backward and decreases the heart's effectiveness.
With the aid of imaging methods like echocardiography or fluoroscopy, these devices are typically inserted through blood vessels like the femoral artery or the subclavian artery and guided to the heart.
Once in place, the device is used to replace or repair the damaged valve, restoring normal blood flow and reducing valve disease symptoms.
It is important to remember that depending on the nation and the medical facility, transcatheter valve-repair devices and the specific procedures may not be available.
A multidisciplinary team of cardiologists, cardiac surgeons, and interventional specialists typically decides whether to use these devices after assessing each patient's situation to determine the best course of action.
Transcatheter valve-repair devices have revolutionized the treatment of heart valve diseases by giving patients who might not be good candidates for open-heart surgery a less invasive alternative.
These devices do, however, come with risks, just like any medical procedure, so patients should speak with their doctors to decide the best course of action for them, given their unique set of circumstances.
The global transcatheter valve-repair devices market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Following approval from the US Food and Drug Administration (FDA), Medtronic has introduced the Evolut PRO+ transcatheter aortic valve replacement (TAVR) System in the US.
Patients with symptomatic, severe aortic stenosis who are at high or extremely high risk for open heart surgery can be treated with the Flex Nav TM transcatheter aortic valve replacement (TAVR) system.
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.